RE:RE:50 millions sharks shares...enriquesuave wrote: My guess is that they are expecting BTD sooner, or have a JV or licensing deal close by and won't need to dilute as much. Hence this new non broken PP. just IMHO
wildbird1 wrote: Contrary to some, I am pleased with this new offering.
Let's see the facts.
1) A non-brokered private placement, give priority to "management & insiders plus accredited investors" on the offering.
2) The RCC(Research Capital Corporation) offering would have added approximately 50 millions shares to the total shares count.
3) This new offering will add approximately 12 millions shares to the total shares count.
My take on this offering is, it doesn't matter why the RCC offering was terminated( in the PressRelease no reasons given), a much smaller offering of just 12 millions shares in the hands of TLT insiders is much better than 50 millions sharks shares.
In short...
12 millions shares in the hands of TLT insiders versus 50 millions sharks shares in the hands of suspicious investors... This new offering is a plus for all TLT small & big investors.
I agree with Enriquesuave & Cashascars, there must be a very good reason why the RCC offering was terminated other than a lack of interest.
What we know without a doubt is that TLT-Ruvidar is superior to anything out there.
TLT-Ruvidar data are superior to Keytruda.
TLT-Ruvidar data are superior to Adstiladrin.
TLT-Ruvidar data are superior to N803+BCG.
Note:
N803+BCG has a very good CR%, but it can't treat the following patients...
-Patients that have a life expectancy of less than 2 years.
-Patients that have inadequate organ functions(almost every older patients).
-Patients that have clinical signs of severe cardiac dysfunctions.
-Patients that have had other cancer within the last 5 years.
If you add all the above patients you end up with a huge numbers of patients that can't receive N803+BCG.
TLT-Ruvidar is 100% safe and has no major restrictions and will treat all the above patients(the FDA must love that 100% safe thing).
The facts that TLT-Ruvidar is superior to Adstiladrin & N803+BCG that have both received the FDA BTD approval is what is keeping my spirit alive.
Important note: As we speak TLT-Ruvidar has a foot inside the FDA process and the FDA has demonstrated absolutely no objections to TLT-Ruvidar, the FDA is just asking for some extra data and some clarifications.
The insiders that are buying the new offering have a very good understanding of what is coming in the short term, it must be good news if these insiders are willing to put up front money to accumulate more TLT shares.
The more I look at this new offering the more I like it.